GlassScriptPhysician profile
Ashley T Ngo
NPI 1891374294
$1,759.58
in general payments reported to CMS, 2019-2025
25 companies · $1,528 in 2025
The $1,528 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $232 · 2025: $1,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $559.23 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Ibsa Pharma INC. | $188.81 | 2024-2025 | Tirosint, Licart, Flector |
| Lilly USA, LLC | $137.65 | 2025 | Mounjaro, Zepbound, Kisunla |
| Exact Sciences Corporation | $102.19 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $99.21 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $90.20 | 2024-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $73.54 | 2024-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $50.23 | 2024-2025 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $46.21 | 2025 | |
| Optinose US, INC. | $45.75 | 2024-2025 | |
| Shield Therapeutics INC | $43.17 | 2024-2025 | |
| Pfizer INC. | $33.39 | 2025 | |
| Amgen INC. | $33.10 | 2024-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.88 | 2025 | Xifaxan |
| Abbvie INC. | $29.33 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $28.62 | 2025 | Gemtesa |
| Renalytix Ai, INC. | $23.81 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Axsome Therapeutics, INC. | $21.16 | 2025 | Symbravo |
| Ascendis Pharma Endocrinology INC | $21.06 | 2025 | Yorvipath |
| Alvogen INC | $20.05 | 2024 | Teriparatide |
| Hologic Sales and Service, LLC | $18.62 | 2025 | Aptima, Thinprep 2000 Processor |
| Currax Pharmaceuticals LLC | $17.87 | 2025 | Contrave |
| Merck Sharp & Dohme LLC | $15.65 | 2025 | Gardasil 9, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $14.49 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.36 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Ngo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.